Gates Package — page 79

From: "Fauci, Anthony (NIH/NIAID) [E]" </O=NIH/OU=NIHEXCHANGE/CN=NIAID/CN=AFAUCI> To: "Koup, Richard (NIH/VRC) [E]" <HEomail.nih.gov>, "Mascola, John (NIH/VRC) [E]" @mail.nih.gov> Ce: "Conrad, Patricia (NIH/NIAID) [E]" <{f@niaid.nih.gov> Subject: RE: Support on Ebola Date: Fri, 08 Aug 2014 13:25:34 -0400 Importance: Normal Thanks, Rick. Very helpful. From: Koup, Richard (NIH/VRC) [E] Sent: Friday, August 08, 2014 9:15 AM To: Mascola, John (NIH/VRC) [E]; Fauci, Anthony (NIH/NIAID) [E] Subject: RE: Support on Ebola John and Tony: Here is the latest I know. We have been getting a lot of additional clarifying questions from BARDA subsequent to our telecom, so I am fairly confident they will fund production of 1 "lot" of vaccine, but I remain unclear as to when we will hear definitively. Wellcome Trust seems willing to provide half the funds for another lot, but only if GSK or some other source partners for the other half of the funds. GSK leadership is not interested, but Rip Ballou is checking with MRC and others to see what can be done. WHO is anxious to start additional small phase 1 trials in Africa (20 subjects per country, at MRC sites). We currently have adequate vaccine stock for our NIH-based phase 1, an expanded phase 1 in Uganda (100 subjects with MHRP), and 1 or 2 other African phase 1 trials. Whether the funding comes to us or GSK, we will both use a contract mechanism to have the vaccine produced at Advent, which is the Okairos facility that made the first lot for us under contract. Our pilot plant would do the vialing and lot release would be shared by us and Okairos. Maybe more info than you wanted. Rick Richard A. Koup, MD Chief, Immunology Laboratory Deputy Director Vaccine Research Center, NIAID, NIH 40 Convent Drive, MSC 3022 Building 40, Room 3502 Bethesda, MD 20892 mail. The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives. From: Mascola, John (NIH/VRC) [E] Sent: Friday, August 08, 2014 8:49 AM To: Fauci, Anthony (NIH/NIAID) [E]